Novel insights into lipoprotein(a): News from Atherosclerosis

Lipoprotein(a) [Lp(a)] has had a varied history. While numerous epidemiologic studies documented an association of elevated Lp(a) levels with increased risk of cardiovascular disease [1], it was not until the advent of genetic studies, especially those using a Mendelian randomization design, that the association with cardiovascular outcomes, including myocardial infarction (MI) and ischaemic stroke, as well as aortic valve stenosis, was demonstrated [2 –10]. Collectively, these findings prompted expert reappraisal and reconsideration of Lp(a) in clinical guidelines [11–13] and catalysed the development of novel therapeutic approaches to managing elevated Lp(a).
Source: Atherosclerosis - Category: Cardiology Authors: Source Type: research